In this peer reviewed editorial for Informa Healthcare, Carmela De Luca discusses a recent agreement between Merck and The Medicines Patent Pool (MPP) to license intellectual property relating to pediatric formulations of its integrase HIV drug. The Agreement is alleged to clear the way for cheaper formulas, novel formulations and combinations, and provide license to manufacture versions of the drug anywhere in the world. However, the Agreement has also been criticized as merely a public relations exercise. De Luca explores this criticism and unpacks the agreement in addressing the question.
Click here to access the article which has been published in final form.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
